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e-mail address: jchacko@uams.edu (J.G. Chacko).Joseph G. Chacko a,⇑, J. Anthony Chacko b, Michael W. Salter aAbstractGiant-cell arteritis (GCA) is a systemic autoimmune disease affecting primarily the elderly. Giant cell arteritis can cause sudden and
potentially bilateral sequential vision loss in the elderly. Therefore, it is considered a medical emergency in ophthalmology and a
significant cause of morbidity in an increasingly aging population. Ophthalmologists need to be able to recognize the classic
symptoms and signs of this disease, and then be able to work-up and treat these patients in an efficient manner. An in-depth
review of GCA from the literature as well as personal clinical experience follows.
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Giant cell arteritis (GCA), also known as temporal or cra-
nial or granulomatous arteritis, is a systemic autoimmune dis-
ease affecting primarily the elderly. It is characterized by
granulomatous inflammation of the large and medium-sized
arteries. GCA is most prevalent in the white population of
European origin. There is an association with HLA-DR4 and
HLA-DRB1 which suggests a genetic predisposition.1 Most
patients affected are over the age of 60 years. The mean
age is 70 years old. Women are affected more often. The inci-
dence can be as high as 27 cases in 100,000 people aged
greater than 50 years old. With the rapidly growing propor-
tion of older persons in most developed countries, the inci-
dence of GCA will most likely increase.2
Permanent visual loss has been reported to occur in as
high as 15–20% of these patients,3 making early and correct
diagnosis critical.4 Several attempts, such as the American
College of Rheumatology (ACR) criteria,1 have been made
to diagnosis GCA without temporal artery biopsy. However,Murchison et al. found that the use of ACR criteria alone
could miss up to 25% of GCA diagnoses.5 Thus, temporal
artery biopsy remains the diagnostic gold standard for
GCA.
The symptoms of giant cell arteritis can overlap with its
cousin disease polymyalgia rheumatica (PMR). PMR similarly
is an autoimmune disease that affects the elderly. Its hallmark
symptoms include muscle pain and weakness affecting the
large muscle groups especially in the hips and shoulders.
Patients with PMR have trouble getting out of a chair and
reaching for objects in cupboards. PMR symptoms also
include low-grade fever, malaise, poor appetite, and weight
loss. When symptoms affect the neck and higher, giant cell
arteritis can be at work. Five to 15% of PMR patients will
be diagnosed with giant cell arteritis, and 50% of giant cell
arteritis patients have PMR symptoms.
The medium-sized extracranial arteries are most fre-
quently affected clinically in GCA. However, occasionally,
the aorta and its branches to the arms and neck or elsewhere
are involved.1e:
al.com
5, USA
Figure 1. Anterior ischemic optic neuropathy (AION) is characterized by
a swollen optic disk accompanied by hemorrhages.
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The classic systemic symptoms of GCA include headache,
scalp tenderness, and jaw claudication. Headache especially
located at the temples is the most common symptom. Jaw
claudication is the most specific symptom. It is important to
remember that jaw claudication means pain with chewing.
This symptom is not constant jaw pain. Patients develop a
significant jaw ache while chewing, so they decrease their
food intake and thereby lose weight and feel weak. A good
way to ask about scalp tenderness is to ask whether combing
or brushing the hair hurts the scalp. Infrequently, a patient
may notice an inflamed artery on the scalp or temple and tell
his or her doctor that it is tender leading to the diagnosis.
GCA patients may also suffer from ear pain and neck pain.
Again they may share the symptoms of PMR with intermittent
low-grade fever, weight loss, malaise, and joint/muscle pain.Figure 2. The pallid disk swelling may have a chalky white appearance inVisual symptoms
Sudden, severe, and sequential vision loss is the hallmark
of giant cell arteritis. The vision loss is usually discovered
upon awakening in the morning. Visual acuity is usually less
than 20/200 in greater than 60% of patients who lose vision.
The fellow eye usually gets involved within days to weeks of
the initial eye. In addition to causing a sudden permanent
vision loss, GCA can present weeks earlier with amaurosis
fugax or a temporary loss of vision which is due to partial
occlusion of the short posterior ciliary arteries or central ret-
inal artery causing transient ischemia. GCA may initially also
present with diplopia or eye pain.6 Cranial nerve palsies
(3, 4, or 6) or ischemic myopathy may rarely occur. This
reinforces the point that any elderly patient presenting to
the eye clinic with visual symptoms or eye pain should be
considered to be a GCA suspect until proven otherwise. This
mode of thinking will help minimize permanent vision loss in
GCA patients.GCA.AION in GCA
Sudden vision loss in GCA occurs most often due to an
inflammatory thrombosis of the short posterior ciliary arter-
ies. The short posterior ciliary arteries form a fine vascular
network that supplies the optic disk. When these vessels
become thrombosed with inflammation, a stroke to the optic
disk occurs. This is called anterior ischemic optic neuropathy
or AION (Fig. 1). AION is characterized by a swollen optic
disk accompanied by hemorrhages and sometimes exudates.
The swollen optic disk may have a chalky white appearance in
GCA. This pallid swelling (Fig. 2) is due to the extreme ische-
mia of GCA. Rarely, the ischemia to the optic nerve occurs
posteriorly, and therefore there is no disk swelling. In this
instance, it is called posterior ischemic optic neuropathy or
PION.
GCA may also sometimes cause a central retinal artery
occlusion (CRAO). About 5% of patients over age 50 with
CRAO have GCA. A classic cherry red spot in the macula
occurs, but no cholesterol or calcific embolus will be seen
since again this is due to an inflammatory thrombosis. GCA
may also rarely cause a cilio-retinal artery occlusion or ocular
ischemic syndrome. The ocular ischemic syndrome is charac-
terized by eye pain, iritis, and hypotony.About 5–10% of anterior ischemic optic neuropathy
(AION) cases over the age of 60 are due to giant cell arteritis.
The other 90–95% are due to garden-variety non-arteritic
ischemic optic neuropathy (NAION). The risk factors for
NAION include the disk-at-risk appearance of the optic disk
(cup-to-disk ratio < 0.1), nocturnal hypotension (taking blood
pressure medicines at night), sleep apnea, uncontrolled
hypertension, diabetes, and tobacco abuse.
Bilateral involvement of anterior ischemic optic neuropa-
thy in temporal arteritis is not uncommon. In untreated cases,
it occurs 54–95% of the time. Cotton wool spots may also be
seen in the retina and indicate concurrent retinal ischemia.
Fluorescein angiography (FA) may be helpful to identify cho-
roidal hypoperfusion and aid in the timely diagnosis of GCA.7Laboratory diagnosis
The two most important labs to order to help make the
diagnosis of GCA are the Erythrocyte Sedimentation Rate
(ESR) and the C-Reactive Protein (CRP). These two lab values,
if elevated, indicate systemic inflammation. If either blood
value is high, this may point you to a diagnosis of GCA, but
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elevated from other causes of systemic inflammation like
infection, malignancy, Diabetes, or other auto-immune dis-
eases like Lupus or Rheumatoid arthritis. Top normal for
ESR in men can be calculated by Age divided by 2, women
(Age + 10) divided by 2.8 This rule may disagree with normal
values from individual laboratories but tends to be more
correct.
The combination of ESR and CRP is 97% specific for the
diagnosis of GCA according to Hayreh et al.9 In Dr. Hayreh’s
study, the CRP was 100% sensitive for detection of GCA. The
ESR was 92% sensitive. The mean ESR value in GCA cases in
this study was 70 mm/h. However, the ESR can be normal in
up to 16% of cases. Parikh et al. reported a sensitivity of 99%
when ESR and CRP were used together.10 Only 1 of their 119
biopsy-proven GCA patients (0.8%) had normal ESR and
CRP. Two patients (1.7%) had a normal CRP with an elevated
ESR.
Thrombocytosis or increased platelets is also a sign of
active inflammation in the body, so it is wise to order a com-
plete blood count (CBC) at the same time as ESR and CRP to
help cinch the diagnosis. Elevated platelet counts and CRP
can be more sensitive inflammatory markers than ESR.2,11
Also ordering the CBC is important to check for anemia,
since the ESR tends to rise with anemia.Occult GCA
There is an entity called occult giant cell arteritis which
occurs about 20% of the time. In this special form of GCA,
there is an absence of the systemic symptoms listed above.
It is defined as ocular involvement by GCA without any
systemic symptoms or signs. Hayreh et al. published a
prospective study in 1998 which included 85 patients with a
positive temporal artery biopsy and ocular involvement.
Eighteen of these 85 patients or 21% had occult GCA.12
The ESR and CRP lab values in this occult group were signif-
icantly lower than the rest of the patients however the results
were still abnormal. In this occult GCA group, 17 of the 18
patients or 94% had anterior ischemic optic neuropathy,
while 2 of the 18 patients or 11% had central retinal artery
occlusion. A normal ESR or CRP may not rule out GCA nor
does a lack of systemic symptoms. The physician must watch
out for early massive visual loss (counting fingers vision or
worse), sequential vision loss within days or weeks, and
chalky white disk edema.
Management
The management of a suspected GCA patient must be
done quickly because there is a risk of permanent sequential
vision loss (blindness) if treatment is delayed. This is why
giant cell arteritis is the number one medico-legal entity in
ophthalmology in the developed world. The physician must
carefully review the three aspects of the patient’s clinical pre-
sentation: history, examination, and lab results. You suspect
that the patient may have giant cell arteritis due to the
history: he or she admits to headaches at the temples, scalp
tenderness, neck pain, malaise, weight loss, low-grade fever,
and/or jaw claudication. Your ophthalmic examination is
consistent with GCA: Swollen or chalky white disk, CRAO,
cotton wool spots in the retina, choroidal hypoperfusion onFA, and/or tender temporal artery. Lastly, stat ESR or CRP
or both are elevated on the lab review.
A good rule of thumb is if 2 out of the 3 above parameters
are positive, treatment and temporal artery biopsy must
follow. The temporal artery biopsy is considered the gold
standard in diagnosis. But do not wait for the results of the
temporal artery biopsy before treating the patient. You must
begin high-dose steroids immediately. Oral prednisone
should be started at a dose of 1 milligram/kilogram per
day. Try to have prednisone tablets available in your office
or clinic to give to the patient to start immediately; if not,
the patient may develop blindness before they have their
prescription filled. If in your judgment, you believe the
patient is too ill to go home, it is always a good idea to admit
the patient to the hospital for IV Solu-Medrol 250 milligrams
every 6 h for 3–5 days followed by high dose prednisone. The
patient should remain on high dose steroids until the
temporal artery biopsy results are completed. If you believe
that there is a low suspicion of GCA, 40 milligrams of
prednisone daily is a good dose to keep patients on till the
biopsy is completed. The temporal artery biopsy should be
scheduled within 1–2 weeks. After this period of time, it is
more difficult to diagnose GCA in the pathologic specimen
due to the steroid’s influence in removing the inflammation
from the artery.13 Although there are other clues in the artery
specimen that may indicate GCA. These signs include the
presence of fibrosis in the artery wall and fragmentation or
loss of the internal elastic lamina (healed arteritis).
High-dose steroid therapy is usually effective in preventing
further visual loss. A few eyes may demonstrate visual deteri-
oration during the first 5 days of treatment, and, conversely,
a few eyes may show a mild improvement in visual acuity with
high-dose corticosteroids.14,15 However, for the most part,
the vision loss is permanent. There is no evidence that
intravenous high dose steroids are more effective than oral
steroids in halting visual deterioration.16
The physician must discuss with the patient and his or her
family about the risks of prednisone use. Side effects include
stomach upset due to acid reflux, increased appetite and
weight gain, osteoporosis leading to fractures with falls,
increased blood sugars in diabetics and blood pressure,
increased anxiety, and poor sleep. Long-term, high-dose
glucocorticoid treatment is not benign and can result in the
development of serious adverse effects including stomach
ulcers, glaucoma, cataracts, bone avascular necrosis, myopa-
thy, and heightened risk for infection. Over-the-counter acid
blockers like ranitidine should be recommended while taking
prednisone to protect the stomach. The prednisone dose
should be taken in the morning to minimize its side effects
of poor sleep. As you can see, prednisone can have marked
side-effects; that is why a positive temporal artery biopsy is
needed to support the continued use of long-term steroids
in these elderly patients.17
When the patient returns for the temporal artery biopsy,
the physician should ask the patient whether the prednisone
helped the GCA symptoms. If the classic GCA symptoms
improved on prednisone, this would correlate well with the
diagnosis of GCA. If the opposite is true, and the patient’s
symptoms of headache, scalp tenderness, and jaw claudica-
tion did not improve with prednisone, this finding would go
against the diagnosis of GCA, even before the biopsy was
done.
Figure 3. Lymphocytic infiltration of the artery wall is seen in active
arteritis.
Figure 4. Multinucleated giant cells in a temporal artery biopsy
specimen.
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of surgeons, including ophthalmologists, ENT specialists,
general surgeons, and plastic surgeons. It can be done in a
minor procedure room under local anesthesia or in the
operating room. It usually takes less than one hour.
Pathologic specimens should be 2–3 cm long because of
the occurrence of skip lesions (discontinuous arterial
involvement) in GCA. False negative results can occur in
3–9%. A contralateral biopsy should be considered after a
negative initial biopsy if clinical suspicion is high for GCA.
It is wise to mark out the course of the superficial temporal
artery with a marking pen while the patient is seated upright
before subcutaneous anesthesia is infiltrated. Also, the
biopsy should be taken on the side of the head which has
more symptoms. Palpate the pulse of the temporal artery
with your fingers or use a Doppler ultrasound. Start at least
2 fingerbreadths above the lateral canthus of the eye. This
will decrease your risk of cutting the facial nerve which travels
with the temporal artery in front of the ear. Other risks of this
surgical procedure include bleeding, bruising, infection,
scalp necrosis, and the possibility of having to repeat the
procedure on the other side.
After being formally diagnosed with GCA via a positive
temporal artery biopsy (the gold standard), the high-dose
prednisone should be tapered very slowly over about 1 year
while monitoring the ESR and CRP lab values periodically.
The clinical response should be assessed as well. Alternate
day steroid treatment is inadequate for GCA. Although it is
expected that the visual prognosis is poor after suffering
ischemic optic neuropathy or central retinal artery occlusion,
the patient’s non-ocular symptoms such as headache, scalp
tenderness, and jaw claudication as well as PMR symptoms
such as muscle pains and weakness should all resolve with
the prednisone. If prednisone’s side effects and risks
outweigh its benefits, a steroid-sparing agent like methotrex-
ate may be used through consultation with rheumatology.
Steroid tapering must be slow and careful because there is
a risk of recurrent ischemic optic neuropathy in 7% of
patients. Recurrent symptoms should prompt re-evaluation.Figure 5. Elastin stain highlights a fragmented or disrupted internal
elastic lamina.Pathologic diagnosis
First of all, make sure that your pathologist is familiar with
this disease. A telephone call in advance may ensure that the
pathologist and ophthalmologist are on the same page
concerning the patient. Multiple cross sections of the tempo-
ral artery will need to be examined under the microscope due
to the occurrence of skip lesions in GCA.
Histopathologically, two patterns are considered diagnos-
tic of giant cell arteritis: those with inflammation of the vessel
wall (active arteritis) and those with post-inflammatory alter-
ations (healed arteritis). With active arteritis (Fig. 3) cellular
infiltration of the artery wall is seen. The adventitia, media,
and intima are thickened with a preponderance of lympho-
cytes, macrophages, and giant cells. It is important to
remember that multi-nucleated giant cells which are a coales-
cence of macrophages (Fig. 4) do not have to be present in a
positive temporal artery biopsy. The primary inciting cause of
the inflammation is unknown but may be due to a bacterial or
viral antigen. Healed arteritis lacks the active inflammation
but will show fibrosis of the vessel wall with disruption of
the internal elastic lamina. Elastin stains may be used tohighlight a fragmented or disrupted internal elastic lamina
(Fig. 5).
Positive biopsies, whether active or healed, are treated
the same initially with high dose steroids. Few investigators
have examined the differences between these two groups
and their outcomes with treatment. Borg et al. found patients
with healed arteritis had lower ESR and higher hemoglobin
levels, theorizing that those with healed arteritis represented
a relatively benign subgroup with milder clinical presentation
and a good prognosis.18 Borg et al. suggested that a lower
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subgroup compared to the active arteritis subgroup which
should begin treatment with an initial dose of prednisone
of 40–60 mg/day or higher. Another rheumatology group,
Lee et al. found similar results.19 These studies were reported
in the rheumatology literature and were focused on the rheu-
matologic signs and symptoms of GCA.
Imaging
Many studies have compared temporal artery ultrasound
findings with histologically proven giant cell arteritis. Ultra-
sound has the highest resolution of all imaging techniques
used for the diagnosis of vasculitis.20 One large meta-analysis
by Karassa et al. showed that sensitivity of temporal artery
duplex ultrasound was 87% and specificity 96%.21 As the
quality of ultrasound technology improves, more centers
are becoming experienced with temporal artery ultrasound,
and in some cases, are replacing temporal artery biopsy with
definitive clinic and ultrasound findings.22
MRA is another modality used to aid in the diagnosis of
vasculitis. In one case series of 7 patients with giant cell arter-
itis, Markl et al. found that 3T high-field MR system had the
ability to detect visualization of inflammatory changes in
the vessel walls of all patients23; however, this imaging tech-
nique is still largely investigational and a protocol to achieve
the finest resolution is still being debated.
Conclusion
Giant cell arteritis is a systemic autoimmune disease of the
elderly that has potentially devastating visual consequences.
Early diagnosis and treatment are critical. This review of
GCA hopefully will help ophthalmologists become better
acquainted with this disease in order to prevent unnecessary
vision loss.
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